⌕
Viridian Therapeutics · VRDN · Nasdaq
Tenet 43 · Weak
Compare
$30.87+1.28%At closeTenet 43 · Weak
$30.87+0.39 (+1.28%)
At close: Nov 13, 2026, 4:00 PM ET· Nasdaq · USD

Viridian Therapeutics (VRDN) Earnings Forecast

Analysts expect Viridian Therapeutics (VRDN) to lose $3.55 a share in FY26, the average of 11 estimates as of Nov 13, 2026.

Sources Analyst estimates EstimatesConsensus as of How we compute thisNot investment advice

16 figures withheld by our checks. Each blank figure names its reason.

FY26 consensus EPS
$−3.55
11 analysts
FY27 consensus EPS
$−2.09
11 analysts · low $−2.47, high $−1.46
EPS revisions, 30 days
+8.5%
$−3.88 to $−3.55
Disagreement, FY26
$0.70
wide, $−3.95 to $−3.25

Consensus estimates only. Analysts' price forecasts and ratings are not licensed here.

Consensus as of Nov 13, 2026 · we check it nightly

Analysts expect Viridian Therapeutics to earn $3.57 a share in FY30; 4 analysts publish an estimate for FY30.

Forward P/E · FY26E
—
$30.87 (as of close, Nov 13, 2026) ÷ $−3.55 consensus EPS
Coverage · FY26
11 · 10
EPS estimates · revenue estimates

Are estimates going up or down lately?

The FY26 EPS consensus is $−3.55, a loss that narrowed 7.8% in 91 days. Every figure compares one fiscal period at both ends.

EPS consensus, change over the last 91 days. One step per nightly change.

−5.7%+7.8%+21.4%FY27 +17.8%FY26 +7.8%Aug 15Nov 13
EPS30 days90 daysshown aboveSince Jul 6
FY2611 analysts▲ +8.5%$−3.88 to $−3.55▲ +7.8%$−3.85 to $−3.55▲ +6.8%$−3.81 to $−3.55
FY2711 analysts▲ +18.5%$−2.57 to $−2.09▲ +17.8%$−2.54 to $−2.09▲ +14.0%$−2.43 to $−2.09
Sep '268 analysts▼ −4.5%$−0.97 to $−1.02▼ −6.4%$−0.95 to $−1.02▼ −7.5%$−0.94 to $−1.02
Dec '268 analysts▲ +22.0%$−0.93 to $−0.72▲ +22.6%$−0.94 to $−0.72▲ +22.6%$−0.94 to $−0.72

Contributors at both ends of the window: FY26 10 and 11. A change in the average can come from a new contributor as much as from a changed mind, so both counts stay in view.

Measured between two of our own nightly snapshots of one fiscal period, so a new fiscal year entering the view is never read as a revision. Never backfilled. A window still filling says how many days it holds; a blank one means our record is not that long yet.

If the Street is right, what does that imply for the share price?

Price as of close, Nov 13, 2026 · consensus as of Nov 13, 2026

EPS is a loss in the years the Street forecasts, and a multiple of a loss is not a price. So the sum switches to EBITDA, from FY28 on, which is the first year the consensus EBITDA is above zero, and waits for your multiple.

Consensus EBITDA · FY29
$0.4B
4 analysts · low $0.3B, high $0.6B · thin coverage
Multiple · EV/EBITDA · yours
No year of positive EBITDA or earnings on record to take a default from, so the multiple can only be yours.
Receipt · VRDN · FY29Nov 13, 2026
Implied, a share
Waiting

The arithmetic will run: EBITDA times your multiple is an enterprise value, plus $0.6B net cash and divided by 0.11B diluted shares, which is a price a share. Net cash from the Sep 30, 2026 balance sheet, diluted shares from the Sep 30, 2026 filing.

This is multiplication, not a forecast. It assumes the market pays the multiple you chose and that the consensus is right. Both are often wrong.

Growth over a negative base is not meaningful. Consensus EPS is a loss in FY26, so there is neither a multiple of those earnings to pay nor a rate to grow from.

How much do analysts disagree?

For FY30, estimates run from $2.00 to $6.57 around an average of $3.57, drawn by 4 analysts.

FY26E11 analysts
$−3.95 to $−3.25 · $0.70 wide
FY27E11 analysts
$−2.47 to $−1.46 · $1.01 wide
FY28E10 analysts
$−0.92 to $3.05 · $3.97 wide
FY29E4 analysts
$1.10 to $3.60 · $2.51 wide
FY30E4 analysts
$2.00 to $6.57 · $4.57 wide

A wide spread is disagreement, not risk; a narrow one is agreement, not accuracy. Later years are always wider because fewer people forecast them. Bars in amber rest on fewer than 15 analysts. The tick on each bar is the average. Spreads are shown in currency rather than as percentages, because a percentage of a number near zero overstates it.

Is next quarter a high bar or an easy one?

Analysts expect Viridian Therapeutics to lose $0.72 a share in the December quarter, the average of 8 estimates. We hold no expected date for the next report.

Expected report
Not held
No expected date is published for this company's next report, so none is printed here.
Revenue expected · December quarter
$49.1M
8 analysts, 40.1 to 63.5 in $M

For the March quarter, analysts expect a loss of $0.67 a share.

Does Viridian Therapeutics usually beat or miss?

We have not been able to check a quarter yet. Our record of estimates for Viridian Therapeutics begins on Jul 6, 2026, and a quarter can be checked only when we hold an estimate for it from before the company reported.

We started recording estimates on Jul 6, 2026, so quarters that reported before that date cannot be checked.

Before our record
Dec '23
Our record, one quarter per report
Mar '24left out
Jun '24left out
Sep '24left out
Dec '24left out
Mar '25left out
Jun '25left out
Sep '25left out
Dec '25left out
Mar '26left out
Jun '26left out
Sep '26left out
Dec '26not reported yet
Checked so far
None yet
one more every report
Beat expectations
Nothing to count
the first check lands after the next report
Share price reaction
Not held
there is no checked quarter to measure a reaction for
Typical gap vs estimate
Not yet
shown once 4 quarters are checked

Checked against the company's reported figure (GAAP) and the average estimate we recorded the night before its results release. Where analysts' number is on an adjusted basis, we leave the comparison out rather than force it. We started recording estimates for Viridian Therapeutics on Jul 6, 2026, so earlier quarters cannot be checked, and we never fill them in after the fact.

The Street expects sales to grow 318.2% in FY27. Consensus EPS is a loss at both ends of that step, so there is no EPS growth rate to take apart.

11 analysts publish an EPS estimate for FY26 and 10 publish revenue. Coverage thins with distance: 4 EPS estimates for FY30. Consensus figures are on the Street's basis and filed figures are GAAP; we label the gap, we do not explain it away.Show coverage by year and over timeHide the coverage chart
Analysts by fiscal year · outlined revenue, filled EPS. Amber marks a panel of fewer than 15.
1011
FY26E
1011
FY27E
1110
FY28E
54
FY29E
54
FY30E
The FY26 panel held 10 analysts when our record of it began on Jul 6, 2026 and holds 11 tonight.

The full consensus, year by year

Consensus as of Nov 13, 2026 · filed figures as reported
Revenue · $Bfiled · consensus average · band = low to high
−0.11.02.2historyStreet forecastFY22FY25FY30E

Coverage thins with distance: 10 revenue estimates for FY26, 5 for FY30.

Diluted EPS · $filed · consensus average · band = low to high
Not enough estimate history to chart yet.

Out-year bands widen as fewer analysts publish: 11 EPS estimates for FY26, 4 for FY30.

Fiscal yearRevenue $BYoYEPS $YoYEBITDA $BNet inc. $BShares BAnalysts rev · EPSFwd P/E
FY25Filed0.1——————as filedn/m
FY26E0.10.1 to 0.1▲6.0%a−3.55−3.95 to −3.25n/ca−0.3−0.30.0910 · 11—
FY27E0.30.3 to 0.4▲318.2%−2.09−2.47 to −1.46—−0.1−0.20.0810 · 11—
FY28E0.70.5 to 1.4▲115.9%0.19−0.92 to 3.05—0.1−0.0−0.0811 · 10164.6×
FY29E1.00.6 to 1.6n/cb1.961.10 to 3.60n/cb0.40.20.085 · 415.8×
FY30E1.30.9 to 2.1▲32.6%3.572.00 to 6.57▲82.3%0.70.30.085 · 48.7×

Average estimate with low to high beneath. Amber counts mark thin coverage and thin rows carry an amber rule. Shares = consensus net income ÷ consensus EPS, a direction rather than a decimal. The filed row's last column is today's price over the last four reported quarters, the one trailing multiple in that column. a This step crosses the seam: last year is a filed GAAP actual and this year is a consensus estimate, so the two are not prepared on one basis. b More than a third of the analyst panel changed between these two years, so the difference of the two averages measures the panel rather than the forecast.

These are consensus estimates: what analysts expect the business to earn, not where they think the stock trades. Coverage thins and the low to high band widens in the out-years. Context, not advice.

Analysts' price forecasts and grades are not licensed here. This page shows forward consensus estimates only: 11 EPS estimates for FY26, 10 for revenue. Not investment advice.

What do analysts expect Viridian Therapeutics to earn in FY26?

Analysts expect Viridian Therapeutics to lose $3.55 a share in FY26, the average of 11 estimates as of Nov 13, 2026.

Install Tenet on your phone

Tenet home pageMethodology© 2026 Tenet Investing Inc.

Data from Intrinio and Financial Modeling Prep.